Ads by Google

Schizophrenia Treatment

TorreyPines Completes Trial Of NGX267 For Treatment Of Cognitive Impairment Associated With Schizophrenia

TorreyPines Therapeutics completed its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS).

Pages